A warm congratulations to our friend prof. Barbara Jereczek-Fossa 🇮🇹on being elected as ESTRO President!

Congratulations Barbara‼️

Best from OncoAlert 🚨 #RadOnc Faculty:

Dr. Miriam Knoll Henning Willers, MD Fumiko Ladd Chino, MD Shankar Siva Percy Lee MD Icro Meattini Mudit Chowdhary, MD Nat Lester-Coll, MD…

G Curigliano MD PhD Thanks Giuseppe, I stand on shoulders of giants, including you

Congratulations to Lillian Siu a Giant in early drug development!

Register to meet Drs. Komal Jhaveri, Javier Cortes MD PhD, G Curigliano MD PhD, & Ian Krop at #ASCO24 for a unique #BreastCancer #MedEd PeerView Live MasterClass educational symposium on 5/31 at 6:30 PM CDT! Developed with partners Living Beyond Breast Cancer & GRASP: bit.ly/2024MBCT

DESTINY-Breast06 will be presented on 6/2 at #ASCO24 by my friend & mentor of many years G Curigliano MD PhD. The trial, announced to be positive, may have a major impact on treatment sequencing and on the definition of HER2. Set your alarm clocks early on Sunday, make sure not to miss it.

Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization - The Lancet thelancet.com/journals/lance…

Tissue agnostic activity of Trastuzumab deruxtecan (T-DXd) in patients with solid tumours harbouring activating HER2 mutations (DESTINY-PanTumor01): primary results LancetOncology G Curigliano MD PhD #bcsm
Full Text link:
sciencedirect.com/science/articl…

When King Charles met King Charles

Charles Swanton UCLH

Their Majesties also met clinicians at the hospital to learn about their use of innovative technology, including CT scanners which are being used to help detect cancer at an early stage.

We’re delighted to share that His Majesty King Charles III will be our new Patron.

This is an exciting time for us and for cancer research. We’re looking forward to the opportunities His Majesty’s Patronage will bring, and know this support will help progress our mission to…

During the visit, our chief clinician, Charles Swanton, highlighted some of the innovative research that Cancer Research UK is supporting at the hospital, including our single biggest investment in lung cancer research, TRACERx.

It’s been lovely to hear how much the visit meant to patients…

Super!

Yes another positive trial! Looking forward to data at ASCO - one big question is impact of sequential therapy. Does sequence matter? Enhertu demonstrated stat significant improvement in PFS in HR+HER2-low MBC after > or = 1 lines of ET in DB06 PhIII trial astrazeneca.com/media-centre/p…

Big news to start the day: DESTINY-Breast06 Phase III trial show a PFS advantage from trastuzumab deruxtecan (T-DXd) compared to chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following 1+ lines of endocrine therapy.…

HER2 is about to change again. In DESTINY-Breast06, T-DXd significantly improved PFS in chemo-naive patients with HER2-low and HER2- #ultralow MBC. OS immature. Presented at ASCO?

Press Release: astrazeneca.com/media-centre/p…

Navigating HER2-low: aacrjournals.org/cancerdiscover…

NEWS FROM INDUSTRY
Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients

➡️showing significant PFS improvements 📈over standard chemotherapy after…

Positive results from Destiny B06: T-DXd demonstrated PFS improvement over chemotherapy in the primary and overall trial population (incl HER2-low and ultralow). #bcsm @oncoalert astrazeneca.com/media-centre/p…

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - businesswire.com/news/home/2024…

I can't wait to be part of this great lineup with Dr. G Curigliano MD PhD and AACR President Patricia M. LoRusso at the Education Session - Emil Lou, MD, PhD, FACP
@AACR ASCO
oncodaily.com/56074.html

#ASCO24 #Cancer #DrugConjugates #OncoDaily #Oncology #UniversityOfMinnesota

What an outstanding #GBCC24 . So honored to be a speaker along with many others ⁦Tari King MD⁩ ⁦IR⁩ Andrea Barrio⁩ #KBCS ⁦G Curigliano MD PhD⁩ ⁦Matteo Lambertini, MD PhD⁩ ⁦European Society of Surgical Oncology (ESSO)⁩ ⁦⁦Marios Konstantinos Tasoulis⁩ ⁦EORTC Breast Cancer Group⁩